ULTRAGENYX PHARMACEUTICAL INC (RARE)
NASDAQ • Healthcare
$25.49
-$0.64 (-2.4%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About ULTRAGENYX PHARMACEUTICAL INC
Name
ULTRAGENYX PHARMACEUTICAL INC
CEO
Emil D. Kakkis
Website
Industry
Healthcare
Year Founded
2010
Employees
1,371
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for rare and ultra-rare genetic diseases and trades on the NASDAQ under the ticker RARE. The company operates in biotechnology within the healthcare sector, sells marketed biologic products, and generated $673.0 million of revenue in FY2025.
Fundamentals & Financials
Revenue (TTM)
$716.9M
Net Income (TTM)
-$586.4M
EPS (TTM)
-$5.84
ROA (TTM)
-46.39%
Current Ratio
1.73
Dividend Yield
0%
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$25.49$24.97 - $26.11
52 Week RangeAvg. Volume$18.29 - $39.891.9M
Market Cap$2.6B
Peers & Related Assets
APGEAPOGEE THERAPEUTICS INC
$134.57-0.0%
CGONCG ONCOLOGY INC
$76.29-1.1%
XENEXENON PHARMACEUTICALS INC
$63.18+1.3%
TVTXTRAVERE THERAPEUTICS INC
$63.9+0.6%
DYNDYNE THERAPEUTICS INC
$26-0.6%
CELCCELCUITY INC
$93.24+0.9%
IDYAIDEAYA BIOSCIENCES INC
$37.93+3.8%
CNTACentessa Pharmaceuticals plc
AAPGAscentage Pharma Group International
SLNOSOLENO THERAPEUTICS INC